Peptide Comparison
VIP (Vasoactive Intestinal Peptide)vsBPC-157
Endogenous neuropeptide with vasodilatory, anti-inflammatory, and immunomodulatory properties
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
At a Glance
Quick
comparison
Dose Range
VIP (Vasoactive Intestinal Peptide)
67 mcg/day–300 mcg/day mcg
BPC-157
250–500 mcg
Frequency
VIP (Vasoactive Intestinal Peptide)
Once daily
BPC-157
Once daily
Administration
VIP (Vasoactive Intestinal Peptide)
Intravenous infusion
BPC-157
Subcutaneous injection
Cycle Length
VIP (Vasoactive Intestinal Peptide)
Ongoing/indefinite
BPC-157
4-6 weeks
Onset Speed
VIP (Vasoactive Intestinal Peptide)
Moderate (1-2 weeks)
BPC-157
Moderate (1-2 weeks)
Evidence Level
VIP (Vasoactive Intestinal Peptide)
Moderate human trials (Phase 1-2)
BPC-157
Strong preclinical (extensive animal studies)
Efficacy
Benefit
ratings
Cardiovascular
Anti-Inflammatory
Neuroprotection
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compound
specifications
VIP (Vasoactive Intestinal Peptide)
Molecular Formula
C147H237N43O43S
Molecular Weight
3325.83 Da
Half-Life
Approximately 1-2 minutes in plasma (rapid enzymatic degradation)
Bioavailability
IV: 100%; Inhaled: local pulmonary delivery; short systemic half-life
CAS Number
37221-79-7
BPC-157
Molecular Formula
C62H98N16O22
Molecular Weight
1419.53 g/mol
Half-Life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS Number
137525-51-0
Protocols
Dosing
tiers
VIP (Vasoactive Intestinal Peptide)
BPC-157
Applications
Best
suited for
VIP (Vasoactive Intestinal Peptide)
Pulmonary arterial hypertension research
VIP (Vasoactive Intestinal Peptide) is particularly well-suited for individuals focused on pulmonary arterial hypertension research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
ARDS and respiratory failure investigation
VIP (Vasoactive Intestinal Peptide) is particularly well-suited for individuals focused on ards and respiratory failure investigation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Anti-inflammatory therapy development
VIP (Vasoactive Intestinal Peptide) is particularly well-suited for individuals focused on anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Neuroprotection studies
VIP (Vasoactive Intestinal Peptide) is particularly well-suited for individuals focused on neuroprotection studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Side
effects
VIP (Vasoactive Intestinal Peptide)
Common
- Facial Flushing
- Diarrhea
- Nausea
Uncommon
- Hypotension
- Tachycardia
- Cardiovascular Effects
Serious
- Hypotension
- Severe Flushing and Facial Erythema
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Research Status
Safety
& evidence
VIP (Vasoactive Intestinal Peptide)
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
VIP (Vasoactive Intestinal Peptide) is a 28-amino acid endogenous neuropeptide with moderate evidence from Phase 1-2 human clinical trials. The synthetic pharmaceutical form (aviptadil/RLF-100) received FDA fast-track designation for COVID-19-associated ARDS, indicating recognition of its therapeutic potential. Critical safety considerations: VIP is a potent vasodilator that causes dose-dependent hypotension and compensatory tachycardia—hemodynamic monitoring is essential during IV administration. Common side effects include facial flushing and diarrhea from its GI effects. Phase 2b/3 COVID-19 ARDS trials (196 patients) reported NO serious drug-related adverse events, a favorable safety signal. However, individual responses to vasodilation vary significantly based on baseline cardiovascular status, medications, and underlying conditions. The peptide's short plasma half-life (1-2 minutes) limits systemic accumulation. Inhaled VIP shows excellent local tolerability for pulmonary applications with minimal systemic absorption.
Contraindications
- xUncontrolled hypotension or hemodynamic instability
- xSevere cardiac decompensation
- xNot approved for clinical use outside of trials
- xInsufficient data for pregnancy and lactation safety
BPC-157
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- xPregnancy
- xBreastfeeding
- xActive cancer
- xHistory of cancer
Decision Guide
Which is
right for you?
Choose VIP (Vasoactive Intestinal Peptide) if...
- Pulmonary arterial hypertension research
- ARDS and respiratory failure investigation
- Anti-inflammatory therapy development
- Neuroprotection studies
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health